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Ethyl pyruvate reduces liver injury at early phase
but impairs regeneration at late phase in
acetaminophen overdose
Runkuan Yang1,2*, Xiaoping Zou3, Marja-Leena Koskinen4 and Jyrki Tenhunen2
Abstract
Introduction: Inflammation may critically affect mechanisms of liver injury in acetaminophen (APAP)
hepatotoxicity. Kupffer cells (KC) play important roles in inflammation, and KC depletion confers protection at early
time points after APAP treatment but can lead to more severe injury at a later time point. It is possible that some
inflammatory factors might contribute to liver damage at an early injurious phase but facilitate liver regeneration at
a late time point. Therefore, we tested this hypothesis by using ethyl pyruvate (EP), an anti-inflammatory agent, to
treat APAP overdose for 24-48 hours.
Methods: C57BL/6 male mice were intraperitoneally injected with a single dose of APAP (350 mg/kg dissolved in 1
mL sterile saline). Following 2 hours of APAP challenge, the mice were given 0.5 mL EP (40 mg/kg) or saline
treatment every 8 hours for a total of 24 or 48 hours.
Results: Twenty-four hours after APAP challenge, compared to the saline-treated group, EP treatment significantly
lowered serum transaminases (ALT/AST) and reduced liver injury seen in histopathology; however, at the 48-hour
time point, compared to the saline therapy, EP therapy impaired hepatocyte regeneration and increased serum
AST; this late detrimental effect was associated with reduced serum TNF-a concentration and decreased expression
of cell cycle protein cyclin D1, two important factors in liver regeneration.
Conclusions: Inflammation likely contributes to liver damage at an early injurious phase but improves hepatocyte
regeneration at a late time point, and prolonged anti-inflammation therapy at a late phase is not beneficial.
Introduction
Acetaminophen (APAP) hepatotoxicity is the major
cause of acute liver failure in the US and Europe [1].
Massive necrosis of the hepatocyte is the feature of
APAP-induced acute liver injury (ALI) [2,3]. Currently,
the underlying mechanisms of APAP toxicity are still
not clear, but inflammation is certainly involved in the
pathogenesis of APAP hepatotoxicity. Neutrophils and
lipopolysaccharide (LPS) have been shown to contribute
to liver injury in APAP overdose [4,5], and pro-inflam-
matory mediator tumor necrosis factor-alpha (TNF-a)
has been shown to promote tissue damage [6-8]. How-
ever, conflicting data are also reported: a significant
reduction in neutrophil accumulation shows no
protection against APAP toxicity [9], and TNF-a is
shown to have a role in repair in APAP liver injury [10].
It is also reported that Kupffer cell depletion confers
protection at early time points after APAP treatment
[11] but can lead to a more severe injury at a later time
point [12]. These data suggest that there is a possibility
that some inflammatory factors contribute to APAP
liver injury at an early injurious phase but that these
factors might also facilitate liver regeneration at a late
phase.
Tissue repair is an important determinant of final out-
come of toxicant-induced injury [13,14]. Since hepato-
cytes are mostly in a quiescent state (G0) [15], pro-
inflammatory cytokines such as TNF-a and interleukin-
6 (IL-6) [15-17] are needed to prime hepatocytes. This
process makes cells more responsive to growth factors.
The exposure to hepatocyte growth factor results in the
expression of cell cycle proteins [15]. The induction of
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cyclin D1 is the most reliable marker for cell cycle (G1
phase) progression in hepatocytes [15]. Once hepato-
cytes express cyclin D1, they have passed the G1 restric-
tion point and are committed to DNA replication [15].
Ethyl pyruvate (EP) is a potent anti-inflammatory
agent and reactive oxygen species (ROS) scavenger
[18,19]. EP can inhibit LPS-stimulated macrophages to
release TNF-a and IL-6 [20]. EP also protects against
liver injury in a couple of murine models such as acute
alcoholic hepatitis [21], hemorrhagic shock [22], sepsis
[23], acute extrahepatic obstruction [24], and acute
necrotizing pancreatitis [25].
In light of this information, we hypothesize that
inflammation might contribute to liver injury at an early
injurious phase but facilitate liver regeneration at a late
time point. We tested this hypothesis by using EP, a
potent anti-inflammatory agent, to treat APAP overdose
for 24 or 48 hours in a murine model.
Material and methods
Materials
All chemicals were purchased from Sigma-Aldrich (St.
Louis, MO, USA) unless noted otherwise.
Animal model and experimental groups
This research protocol complied with regulations pub-
lished by the National Institutes of Health in regard to
the care and use of experimental animals and was
approved by the Institutional Animal Use and Care
Committee of the University of Pittsburgh Medical
School. Male C57BL/6 mice weighing 20 to 25 g (The
Jackson Laboratory, Bar Harbor, ME, USA) were used in
this study. The animals were maintained at the Univer-
sity of Pittsburgh Animal Research Center with a 12-
hour light-dark cycle and free access to standard labora-
tory food and water. The animals were fasted overnight
prior to the experiments.
A single dose (40 mg/kg) of EP has been shown to be
consistently effective to protect against liver injury in
the following animal models: acute alcoholic hepatitis
[21], hemorrhagic shock [22], sepsis [23], acute extrahe-
patic obstruction [24], and acute necrotizing pancreatitis
[25]. Therefore, 40 mg/kg of EP was chosen to treat
APAP overdose in this study. The pilot experiments
showed that serum alanine aminotransferase/aspartate
aminotransferase (ALT/AST) began to rise 2 hours after
APAP administration. Therefore, we started the treat-
ments 2 hours after APAP injection, when the liver
injury began to occur.
In the first experiment, ALI was induced by a single
dose of APAP (350 mg/kg dissolved in 1 mL of sterile
saline) administered by intraperitoneal (i.p.) injection.
Fourteen APAP-challenged mice were then randomly
assigned to the EP group (n = 7) or the saline group (n
= 7). Six mice injected with saline not containing APAP
served as the control group. Two hours after APAP
injection, the animals in the EP group were intraperito-
neally injected with 0.5 mL of EP solution (40 mg/kg
dissolved in 0.5 mL of sterile saline) every 8 hours. The
same amount of saline was given to the saline group or
the control group at equivalent time points. Twenty-
four hours after APAP injection, all surviving mice in
each group were anesthetized with sodium pentobarbital
(90 mg/kg i.p.), serum was collected to measure AST
and ALT, and the left lobe of the liver was stored in
10% formalin for pathology (hematoxylin-eosin, or HE,
staining).
In the second experiment, three separate groups of
mice were used. ALI model and treatment remained the
same as in the first experiment except the treatment
was extended to 48 hours. Forty-eight hours after APAP
injection, all surviving mice in each group were anesthe-
tized with sodium pentobarbital (90 mg/kg i.p.), and the
following procedures were performed: blood was aspi-
rated from the heart to measure serum ALT/AST, the
left lobe of the liver was stored in 10% formalin for
pathology (HE staining), and the rest of the liver tissue
was harvested and frozen for protein extractions.
In the third experiment, three separate groups of mice
were used. ALI model and treatment remained the same
as in the second experiment except the treatment was
given for the first 24 hours only; no further treatment
was given for the 24- to 48-hour time point. Forty-eight
hours after APAP injection, all surviving mice in each
group were anesthetized with sodium pentobarbital (90
mg/kg i.p.), serum was collected to measure ALT/AST,
and the left lobe of the liver was stored in 10% formalin
for pathology (HE staining).
In the fourth experiment, three separate groups of
mice were used. ALI model and treatment remained the
same as in the second experiment except the treatment
was given for the 24- to 48-hour time point only; no
treatment was given for the first 24 hours. Forty-eight
hours after APAP administration, all surviving mice in
each group were anesthetized with sodium pentobarbital
(90 mg/kg i.p.), serum was collected to measure ALT/
AST, and the left lobe of the liver was stored in 10%
formalin for pathology (HE staining).
Serum aminotransferase measurements
Serum levels of AST and ALT were measured at 37°C
with a commercially available kit (from Sigma Diagnos-
tic, part of Sigma-Aldrich).
Histological analysis
Consecutive sections (5 μm) from paraffin-embedded
liver were prepared for HE staining. The percentage of
necrosis was estimated by evaluating the number of
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microscopic fields with necrosis in comparison with the
entire cross-section. In general, necrosis was estimated
at low power (100 ×) and questionable areas were evalu-
ated at higher magnification (200 ×). The pathologist
evaluated all histological sections in a blinded fashion.
Inflammatory cell infiltration results were scored semi-
quantitatively by averaging the number of inflammatory
cells per microscopic field at a magnification of 200 ×.
Five fields per tissue sample were evaluated, and six ani-
mals in each group were examined.
Serum TNF-a and IL-6 concentrations
Blood was obtained by cardiac puncture, and the serum
was collected and stored frozen at -80°C until assayed
for IL-6 and TNF-a by using enzyme-linked immuno-
sorbent assay kits from R&D Systems Inc. (Minneapolis,
MN, USA) in accordance with the instructions of the
manufacturer.
Tissue myeloperoxidase
Neutrophil infiltration was measured at 24 and 48 hours
by determining myeloperoxidase (MPO) activity in liver
tissue homogenates as previously described [26] and was
used as an index of neutrophil infiltration in all groups.
The MPO levels were expressed as units per gram of
tissue (U/g).
Hepatic tissue malondialdehyde
This assay for lipid peroxidation was performed at 24
and 48 hours as previously described [21]. Results were
expressed as nanomoles of malondialdehyde (MDA) per
gram of tissue.
Western blot
Liver protein was extracted as previously described [27].
Equivalent amounts of protein were boiled in sample
buffer and separated on 7.5% pre-cast SDS-polyacryla-
mide gels (Bio-Rad Laboratories, Inc., Hercules, CA,
USA) and transferred to nylon membranes. Membranes
were then probed with a specific antibody against cyclin
D1 (Cell Signaling Technology, Inc., Danvers, MA, USA)
protein, visualized with an enhanced chemiluminescence
substrate (Amersham Pharmacia Biotech, now part of
GE Healthcare, Little Chalfont, Buckinghamshire, UK),
and exposed to x-ray film in accordance with the
instructions of the manufacturer.
Hepatocyte proliferation (DNA synthesis)
At the 24-hour time point, the APAP-challenged mice
showed only occasional hepatocyte nuclei labeled for 5-
bromo-2-deoxyuridine (BrdU) [28]. Therefore, the BrdU
test was performed at only the 48-hour time point in
this study. To evaluate hepatocyte regeneration, mice
from the 48-hour groups were administered BrdU (50-
mg/kg i.p. injection at the 46-hour time point) 2 hours
before they were killed. Parraffin-embedded liver sec-
tions were prepared and processed for immunohisto-
chemistry by using BrdU in situ staining kits from BD
Pharmingen (San Jose, CA, USA) in accordance with the
instructions of the manufacturer. Digital images of five
low-power fields from each liver were obtained in a ran-
dom and blinded fashion, and the number of BrdU-
labeled hepatocyte nuclei was counted. The average
number of BrdU-positive hepatocytes in each animal
was used for subsequent analysis.
Statistical methods
Results are presented as mean ± standard error of the
mean (SEM). Continuous data were analyzed by using
the Student t test or analysis of variance followed by
the Fisher least significant difference test. P values of
less than 0.05 were considered significant. Summary
statistics are presented for densitometry results from
studies using Western blot for cyclin D1 expression,
but these results were not subjected to statistical ana-
lysis since the method employed was only semi-quanti-
tative (n = 6).
Results
Serum alanine aminotransferase/aspartate
aminotransferase
Twenty-four hours after APAP injection, one mouse
from the saline group and one mouse from the EP
group died, and all mice in the control group survived.
Compared with saline treatment, EP therapy decreased
serum concentrations of ALT/AST by a statistically sig-
nificant degree (Figure 1A, B). However, 48 hours after
APAP challenge, EP-treated mice showed a significantly
higher serum AST concentration in comparison with
the saline treatment group (Figure 1C, D). Compared
with early-phase (2 to 24 hours) saline treatment, early-
stage (2 to 24 hours) EP treatment significantly
decreased serum ALT/AST concentrations at 48 hours
(Figure 1E, F). However, compared with late-phase (24-
to 48-hour) saline treatment, late-stage (24- to 48-hour)
EP administration significantly increased serum AST
concentration (*P < 0.05 versus the control group, †P <
0.05 versus the saline group, n = 6 for each group) (Fig-
ure 1G, H).
Liver histopathology
Twenty-four hours after APAP injection, the saline-trea-
ted mice showed 58.4% ± 7.3% necrotic area and a large
number of infiltrating inflammatory cells (386 ± 28 per
high-power field, n = 6); EP treatment statistically
reduced the necrotic area to 35.6% ± 4.6% and signifi-
cantly decreased the number of infiltrating inflammatory
cells (261 ± 17 per high-power field, n = 6, P < 0.05).
Yang et al. Critical Care 2012, 16:R9
http://ccforum.com/content/16/1/R9
Page 3 of 9
Cell boundary loss and ballooning degeneration were
also found around the hepatic central vein in the sal-
ine and EP groups. In histological evaluation 48 hours
after ALI induction, the saline-treated mice demon-
strated 8.6% ± 1.5% necrotic area, evident regenera-
tion, and extensive infiltration of inflammatory cells
(242 ± 35 per high-power field, n = 6) in the centri-
lobular regions. In contrast, EP-treated mice showed
statistically larger necrosis (26.6% ± 3.3%) in the cen-
trilobular region and no evident regeneration was seen
in the EP group; treatment with EP statistically
reduced the number of infiltrating inflammatory cells
(156 ± 24 per high-power field, n = 6). Forty-eight
hours after APAP administration, the early-phase (2-
to 24-hour) saline-treated mice and the late-phase (24
to 48 hours) saline-treated animals showed hepatic
necrosis and inflammatory cell infiltration comparable
to those of the 48-hour saline group (2 to 48 hours)
as described above. Compared with saline treatment,
early EP treatment statistically decreased hepatic
Figure 1 Effect of treatment with saline or ethyl pyruvate on serum transaminases (ALT/AST) in acetaminophen (APAP)-induced acute
liver injury (ALI) model. (A, B) ALI was induced in C57Bl/6 male mice with a single dose of APAP (350 mg/kg) by intraperitoneal (i.p.) injection.
Two hours after APAP injection, the animals were treated with 0.5 mL of saline or 0.5 mL of ethyl pyruvate (40 mg/kg) every 8 hours. ALT and
AST were measured 24 hours after APAP injection (n = 6 survival mice for each group). (C, D) Three separate groups of mice were used. ALI
model and treatments were the same as in (A) and (B) except the treatment was extended to 48 hours. ALT and AST were measured at 48
hours after APAP injection (n = 6 survival mice for each group). (E, F) Three separate groups of mice were used. ALI model and treatments were
the same as in (C) and (D) except there was no further treatment for the 24- to 48-hour time point. ALT and AST were measured at 48 hours
after APAP injection (n = 6 survival mice for each group). (G, H) Three separate groups of mice were used. ALI model and treatments were the
same as in (C) and (D) except the treatment was given only for the 24-hour to 48-hour time point. ALT and AST were measured at 48 hours
after APAP injection (n = 6 survival mice for each group). Results are presented as mean ± standard error of the mean. *P < 0.05 versus control;
†P < 0.05 versus saline. ALT, alanine aminotransferase; AST, aspartate aminotransferase.
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necrosis (3.4% ± 0.3%, P < 0.05) and reduced the
number of infiltrating inflammatory cells (160 ± 28
per high power field, n = 6) at 48 hours. In contrast,
the late EP administration group showed significantly
increased necrosis (23.2% ± 4.2%, P < 0.05, n = 6) and
reduced the number of infiltrating inflammatory cells
(150 ± 34 per high-power field, n = 6) in comparison
with the 48-hour saline group. The hepatic necrosis in
the EP (24- to 48-hour) group was not statistically
smaller than that in the EP (2- to 48-hour) group at
48 hours (P > 0.05). Since the three saline-treated
groups (saline 2- to 48-hour group, saline 2- to 24-
hour group, and saline 24- to 48-hour group) at 48
hours showed comparable pathology, only saline 2- to
48-hour treatment at 48 hours is shown in Figure 2.
Necrosis data are presented in Table 1.
Serum TNF-a and IL-6 concentrations
Twenty-four hours after APAP injection, the serum
TNF-a concentration in the control group was 5.1 ± 3.4
pg/mL, and the TNF-a concentrations in the saline and
Figure 2 Effect of treatment with saline or ethyl pyruvate (EP) on pathology in acetaminophen-challenged mice. Hematoxylin-eosin
staining was assessed 24 and 48 hours after induction of acute liver injury (or sham procedure). Method and treatment were the same as
described in Figure 1 (n = 6 for each group). Since the three saline-treated groups (saline 2- to 48-hour group, saline 2- to 24-hour group, and
saline 24- to 48-hour group) showed comparable pathology, only saline 2- to 48-hour treatment at 48 hours is shown. A typical picture is
shown. (A = 24 h Saline, B = 48 h Saline, C = 2-24 h EP, D = 24 h EP, E = 48 h EP, F = 24-48 h EP).
Table 1 Hepatic necrosis at 24 and 48 hours after
acetaminophen administration
Animal groups 24 hours 48 hours
Saline (2 to 48 hours) 58.4 ± 7.3 8.6 ± 1.5
Ethyl pyruvate (2 to 48 hours) 35.6 ± 4.6a 26.6 ± 3.3a
Saline (2 to 24 hours) 8.8 ± 1.5
Ethyl pyruvate (2 to 24 hours) 3.4 ± 0.3a
Saline (24 to 48 hours) 8.3 ± 1.2
Ethyl pyruvate (24 to 48 hours) 23.2 ± 4.2a
Hepatic necrosis is expressed as a percentage. Acetaminophen dose was 350
mg/kg. Six mice were in each group. aP < 0.05 between the saline treatment
and the ethyl pyruvate therapy.
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EP groups remained the same as in the control group (P
> 0.05, n = 6 for each group). However, at 48 hours, the
serum TNF-a concentration in the saline group was sta-
tistically higher than those in the control and EP groups
(P < 0.05, n = 6 in each group) (Figure 3), and there
was no statistically significant difference between the
control and EP groups. Serum IL-6 concentration was
undetectable in each group at both the 24-hour and the
48-hour time points.
Hepatic tissue myeloperoxidase levels
Tissue MPO activity was determined as an index of neu-
trophil infiltration after APAP injection in the liver. At
the 24-hour time point, the mean liver MPO activity
value for the control group was 4.3 ± 0.3 U/g, and this
value significantly increased to 10.8 ± 0.4 U/g in the sal-
ine group and 7.1 ± 0.3 U/g in the EP group (Figure
4A) (*P < 0.05). Compared with saline treatment, EP
treatment significantly reduced MPO values (P < 0.05).
Forty-eight hours after APAP administration, the mean
liver MPO value for the control group was 4.3 ± 0.3 U/
g, and this value significantly increased to 6.0 ± 0.3 U/g
in the saline group and 6.9 ± 0.4 U/g in the EP group
(Figure 4B) (*P < 0.05), but there was no statistically sig-
nificant difference between the saline group and the EP
group (n = 6 for each group, data were shown as mean
± SEM, *P < 0.05 versus the control group, †P < 0.05
versus the saline group).
Hepatic tissue malondialdehyde concentrations
Neither 24-hour nor 48-hour hepatic tissue MDA con-
centrations were significantly changed in the saline or
EP groups in comparison with the normal control group
(P > 0.05) (Table 2).
Hepatic cyclin D1 expression
The timely onset of tissue repair processes can limit
liver injury and promote regeneration of lost tissue mass
[14]. The induction of cyclin D1 is the most reliable
marker for cell cycle (G1 phase) progression in hepato-
cytes [15]. Western blot was performed by using whole-
cell extracts prepared from liver tissue to assess expres-
sion of cyclin D1 in mice subjected to ALI or the con-
trol procedure. In Figure 5, cyclin D1 expression in the
control group and EP group was minimal. In contrast,
cyclin D1 expression was clearly observed in the saline-
treated animals at 48 hours after APAP administration.
Hepatic BrdU expression
The hepatocyte proliferation was assessed by BrdU
immunohistological staining. BrdU-positive nuclei are
shown by the arrows. At 48 hours, the number of
labeled nuclei (per low power) was significantly
increased in both saline (74 ± 10) (Figure 6B) and EP
(20 ± 5) (Figure 6C) groups though to a statistically les-
ser extent in the EP-treated mice. In addition, the EP
group showed a brown background staining in the cell
plasma of the large necrotic area.
Discussion
The purpose of this study was to test the hypothesis
that inflammation might contribute to liver damage at
an early injurious phase but facilitate liver regeneration
at a late phase in APAP overdose. The major novel find-
ings of this investigation are the following: (a) EP-trea-
ted mice demonstrate decreased serum ALT/AST and
reduced necrosis at 24 hours; however, EP therapy
shows increased serum AST and impaired liver regen-
eration at 48 hours; (b) the late detrimental effect is
associated with a decreased serum TNF-a concentra-
tion; and (c) EP-treated mice demonstrate significantly
reduced expression of cell cycle protein cyclin D1 in
liver tissue.
EP-treated mice demonstrated decreased serum ALT/
AST and reduced necrosis at 24 hours. This early pro-
tective effect was associated with significantly decreased
hepatic MPO and a reduced number of infiltrating
inflammatory cells in comparison with the saline-treated
group. In this study, we also measured 24-hour and 48-
hour hepatic MDA levels, a parameter of hepatic lipid
peroxidation, which were not significantly changed in
the saline or EP groups in comparison with the normal
control group. This MDA result did not support the
notion that the beneficial effect of EP in the early phase
could be attributed to the antioxidant effects of EP. The
serum TNF-a and IL-6 concentrations were not ele-
vated at 24 hours in this model. This result was unex-
pected, and it is possible that 24 hours was not the peak
time for serum TNF-a and IL-6 in this model.
Figure 3 Effect of treatment with saline or ethyl pyruvate (EP)
on serum tumor necrosis factor-alpha (TNF-a) in
acetaminophen-treated mice. Serum TNF-a was assessed at 48
hours after the induction of acute liver injury (or sham procedure).
Results are presented as mean ± standard error of the mean (n =
6). *P < 0.05 versus control; †P < 0.05 versus EP.
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EP impaired hepatocyte regeneration at 48 hours, and
this result was unexpected. Therefore, we repeated the
experiment once more with another dose (80 mg/kg) of
EP, and the result at the 48-hour time point was com-
parable to that of the 40-mg/kg dose. The result did not
show a clear dose-dependent pattern in this model.
Therefore, this study focused on the 40-mg/kg dose of
EP. Currently, there is no evidence that continued ther-
apy with EP might have prevented late-phase toxicity of
APAP. If EP prevented late-phase toxicity of APAP, EP
treatment would be beneficial at 48 hours. However, in
this study, compared with the saline therapy, the EP (2
to 48 hours) treatment and the late-phase EP (24 to 48
hours) therapy both showed increased hepatic necrosis
at the 48-hour time point.
Massive hepatocyte necrosis is the predominant fea-
ture of APAP-induced ALI. Liver regeneration is vital
for survival after a toxic insult [14], and cyclin D1 is an
important cell cycle protein [15]. In this study, Western
blot showed that EP treatment markedly decreased the
level of cyclin D1 in the APAP-challenged liver tissue.
The decreased cyclin D1 expression was associated with
increased serum AST and impaired liver regeneration in
EP-treated mice receiving APAP, suggesting that EP
therapy likely impairs liver regeneration via a cyclin D1-
mediated pathway.
EP-treated mice demonstrated higher serum AST and
impaired hepatocyte regeneration at the 48-hour time
point. This could be due to the decreased pro-regenera-
tive cytokine TNF-a level because TNF-a might prime
hepatocytes for regeneration.
After 24 hours, MPO levels and the number of inflam-
matory cells were lower in the EP group in comparison
with the saline group. This could be secondary to the
significantly larger degree of necrosis seen in the saline
group after 24 hours. In this investigation, at the 48-
hour time point, EP treatment did not reduce MPO
level in comparison with the saline therapy. This is
probably because EP delayed hepatocyte regeneration
and a larger necrotic area remained in the EP group,
and the large necrotic tissue might attract more neutro-
phil infiltration.
In this study, compared with the 48-hour saline group,
early-phase (2 to 24 hours) EP-treated mice demon-
strated statistically smaller necrosis at 48 hours. It is
likely that early EP treatment reduced liver injury at 24
hours. Therefore, the EP group might have smaller
hepatic necrosis at the 24-hour time point in compari-
son with the saline group. Smaller necrosis in the EP
group might heal more quickly than the bigger necrosis
in the saline group while approaching the 48-hour time
point, and early EP therapy probably did not markedly
impair hepatocyte regeneration. In contrast, late-phase
(24 to 48 hours) EP therapy (without early-phase treat-
ment) showed significantly increased hepatic necrosis at
48 hours in comparison with the saline group, suggest-
ing that inflammation facilitates hepatocyte regeneration
at a late phase, and anti-inflammatory therapy at a late
phase is not beneficial.
Currently, N-acetyl-cysteine (NAC), a glutathione pre-
cursor, is the antidote for APAP overdose [29].
Figure 4 Effect of treatment with saline or ethyl pyruvate (EP) on hepatic myeloperoxidase (MPO) activity in mice with acute liver
injury (ALI). Liver MPO was assessed 24 hours (A) and 48 hours (B) after induction of ALI (or sham procedure). Results are presented as mean
± standard error of the mean (n = 6). *P < 0.05 versus control; †P < 0.05 versus EP.
Table 2 Effect of treatment with saline or ethyl pyruvate
on liver malondialdehyde concentrations in the control
or acetaminophen-injected mice
Animal groups 24 hours 48 hours
Control 8.1 ± 1.4 8.0 ± 1.3
Saline 9.3 ± 1.6 9.1 ± 1.4
Ethyl pyruvate 8.3 ± 1.3 8.3 ± 1.2
Malondialdehyde concentrations are expressed as nanomoles per gram of
tissue and presented as mean ± standard error of the mean. Acetaminophen
dose was 350 mg/kg. Six mice were in each group. P > 0.05 among each
groups.
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However, this antidotal therapy is effective for early-pre-
senting patients and is less effective for late-presenting
patients [29,30]. Therefore, additional therapies are
needed. In this study, EP therapy protected against liver
injury at an early phase. However, at a late time point,
even though there was a large number of infiltrating
inflammatory cells, the anti-inflammation therapy with
EP impaired hepatocyte regeneration. More investiga-
tions are needed to reevaluate the role of inflammation
in APAP hepatotoxicity.
Conclusions
Inflammation likely contributes to liver injury at an early
phase but facilitates hepatocyte regeneration at a late
time point in APAP hepatotoxicity, and prolonged anti-
inflammation therapy at a late phase is not beneficial.
Key messages
• Ethyl pyruvate (EP) treatment reduces liver injury
at 24 hours after acetaminophen (APAP) challenge.
This early protective effect is associated with
decreased hepatic myeloperoxidase and a reduced
number of infiltrating inflammatory cells.
• EP therapy impairs liver regeneration at 48 hours
after APAP overdose. This effect is associated with
reduced serum tumor necrosis factor-alpha and
decreased cyclin D1 level.
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